• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

4.400 -0.100 (-2.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CAMP4 Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Today 16:05 EDT
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
May 07, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
April 28, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder 
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
March 18, 2026
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions. 
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
March 18, 2026
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies. 
Via The Motley Fool
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
March 06, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
March 05, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
November 29, 2025
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
November 18, 2025
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
November 18, 2025
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 06, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
3 Healthcare Companies Insiders Are Buying ↗
October 14, 2025
Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years. 
Via MarketBeat
Topics Initial Public Offering
News headline image
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
October 01, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
September 10, 2025
 
Via Benzinga
News headline image
Wednesday's after hours session: top gainers and losers ↗
September 10, 2025
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
September 10, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
September 10, 2025
 
Via Benzinga
News headline image
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
September 10, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Camp4 Reports Q2 Revenue Beats Estimates ↗
August 14, 2025
Via The Motley Fool
News headline image
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 14, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
July 28, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap